



TECHNOLOGY AVAILABLE FOR LICENSING

Biaryl Amino Acids as Modulators of Nuclear Receptor Coregulatory Protein Binding

Non-Provisional Patent Application #PCT/US09/37986

Inventor: Robert Hanson

Invention Details:

This invention describes novel synthesized compounds that modulate hormone receptors. Use of these compounds allows for a more specific and targeted approach to the modulation process. The ability to block a very small subset of responses within the large field results in a much more focused therapy with fewer side effects. Users will be able to make many different variations in order to match a particular disorder. The applications for this technology are broad and wide-ranging.

Benefits of the Invention:

Advantages:

- Increased selectivity
- Higher specificity and targeting
- More stable than peptides
- Fewer side effects
- Orally active
- “Personalized medicine”
 - Many variations may be made to match a particular disorder

Applications:

- Wide range of endocrine disorders
 - Diabetes
 - Obesity
- Treatment of inflammation
- Hormone replacement therapy
- Treatment of cancer (i.e. breast, prostate, etc.)

The Bottom Line:

Data from this research has been tested in vitro with excellent results. This invention will allow for generation of compounds in a broad variety of pharmacology. Previous approaches for modulating hormone receptor function have broad side effects, and have difficulty controlling selectivity. In comparison, this approach has much better selectivity and fewer side effects.

For More Information:

Please contact:

Susan Riley Keyes, J.D., Ph.D.

Technology Transfer Executive
Northeastern University, OTIC
360 Huntington Ave, 960 RP
Boston, MA 02115-5000

Phone: 617-373-8810

Fax: 617-373-8866

Email: a.pirri@neu.edu

or

Robert Hanson, Ph.D.

Dept. of Chemistry & Chemical Biology
Northeastern University
360 Huntington Avenue
Boston, MA 02115-5000

Phone: 617-373-3313

Fax: 617-373-8795

Email: r.hanson@neu.edu